BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 15948119)

  • 1. Overexpression of laminin-5 gamma2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: association with expression of cyclooxygenase 2, epidermal growth factor receptor [corrected] and human epidermal growth factor receptor [corrected] 2.
    Kiyoshima K; Oda Y; Kinukawa N; Naito S; Tsuneyoshi M
    Hum Pathol; 2005 May; 36(5):522-30. PubMed ID: 15948119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
    Kramer C; Klasmeyer K; Bojar H; Schulz WA; Ackermann R; Grimm MO
    Cancer; 2007 May; 109(10):2016-24. PubMed ID: 17394193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cox-2 and Her2/neu co-expression in invasive bladder cancer.
    Eltze E; Wülfing C; Von Struensee D; Piechota H; Buerger H; Hertle L
    Int J Oncol; 2005 Jun; 26(6):1525-31. PubMed ID: 15870865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
    Korkolopoulou P; Givalos N; Saetta A; Goudopoulou A; Gakiopoulou H; Thymara I; Thomas-Tsagli E; Patsouris E
    Hum Pathol; 2005 Aug; 36(8):899-907. PubMed ID: 16112007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases.
    Guo CC; Fine SW; Epstein JI
    Am J Surg Pathol; 2006 Jul; 30(7):883-91. PubMed ID: 16819332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group.
    Chakravarti A; Winter K; Wu CL; Kaufman D; Hammond E; Parliament M; Tester W; Hagan M; Grignon D; Heney N; Pollack A; Sandler H; Shipley W
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):309-17. PubMed ID: 15890569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder.
    Shariat SF; Matsumoto K; Kim J; Ayala GE; Zhou JH; Jian W; Benedict WF; Lerner S
    J Urol; 2003 Sep; 170(3):985-9. PubMed ID: 12913755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
    Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
    Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of EIF-5A2 is an independent predictor of outcome in patients of urothelial carcinoma of the bladder treated with radical cystectomy.
    Chen W; Luo JH; Hua WF; Zhou FJ; Lin MC; Kung HF; Zeng YX; Guan XY; Xie D
    Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):400-8. PubMed ID: 19155439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications.
    Popov Z; Gil-Diez-De-Medina S; Ravery V; Hoznek A; Bastuji-Garin S; Lefrere-Belda MA; Abbou CC; Chopin DK
    Urol Oncol; 2004; 22(2):93-101. PubMed ID: 15082004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor, MUC-1 and MUC-2 in bladder cancer.
    Cardillo MR; Castagna G; Memeo L; De Bernardinis E; Di Silverio F
    J Exp Clin Cancer Res; 2000 Jun; 19(2):225-33. PubMed ID: 10965823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas.
    Ettl T; Schwarz S; Kleinsasser N; Hartmann A; Reichert TE; Driemel O
    Histopathology; 2008 Nov; 53(5):567-77. PubMed ID: 18983466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
    Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
    Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 protein overexpression and gene amplification in upper urinary tract transitional cell carcinoma: systematic analysis applying tissue microarray technique.
    Langner C; Gross C; Rehak P; Ratschek M; Rüschoff J; Zigeuner R
    Urology; 2005 Jan; 65(1):176-80. PubMed ID: 15667899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New markers for pharmacological targeting in bladder cancer with lymph node metastasis].
    Herrmann E; Eltze E; Köpke T; Bolenz C; Bierer S; Neumann J; Hertle L; Wülfing C
    Aktuelle Urol; 2007 Sep; 38(5):392-7. PubMed ID: 17907066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.
    Krüger S; Lange I; Kausch I; Feller AC
    Anticancer Res; 2005; 25(1A):263-71. PubMed ID: 15816547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer.
    Matsubara J; Yamada Y; Hirashima Y; Takahari D; Okita NT; Kato K; Hamaguchi T; Shirao K; Shimada Y; Shimoda T
    Clin Cancer Res; 2008 May; 14(10):3022-9. PubMed ID: 18483367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of cyclooxygenase-2 expression on tumor vascularity in advanced stage ovarian serous carcinoma.
    Ali-Fehmi R; Che M; Khalifeh I; Malone JM; Morris R; Lawrence WD; Munkarah AR
    Cancer; 2003 Oct; 98(7):1423-9. PubMed ID: 14508829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor, cyclooxygenase-2, and BAX expression in the primary non-small cell lung cancer and brain metastases.
    Milas I; Komaki R; Hachiya T; Bubb RS; Ro JY; Langford L; Sawaya R; Putnam JB; Allen P; Cox JD; McDonnell TJ; Brock W; Hong WK; Roth JA; Milas L
    Clin Cancer Res; 2003 Mar; 9(3):1070-6. PubMed ID: 12631609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
    Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
    Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.